DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2022 của Fresh Tracks Therapeutics, Inc.

Fresh Tracks Therapeutics, Inc. was built from and is guided by this belief. In turn, they strive to identify, pursue, and develop groundbreaking therapeutics to help millions of people struggling with devastating autoimmune, inflammatory, and other debilitating diseases. Together, the executive management team and board of directors have a proven track record of leadership across early-stage … More research, product development, and global commercialization. They have served in leadership roles at large global pharmaceutical and biotech companies that successfully developed and/or launched first–in–class products, including Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta®, Juvederm®, Pluvicto®, and Sofpironium Bromide. They align this expert knowledge and clear vision to explore beyond the limitations of current therapies and accomplish something exceptional.

TÊN CÔNG TY / COMPANY
Fresh Tracks Therapeutics, Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NASDAQ (US)

MÃ CHỨNG KHOÁN / TICKER
FRTX

KỲ BÁO CÁO
2022

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare

LƯU Ý

  • Xin vui lòng đợi một lát để Báo cáo được tải về, tùy thuộc vào dung lượng của Báo cáo mà thời gian có thể nhanh hoặc chậm.
  • Báo cáo chỉ cho phép xem từ Việt Nam.